Derby City Direct Primary Care - Louisville, KY

DelRicht Research

Human Influenza

Cidara Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when given as a single dose via 3 subcutaneous (SQ) injections to adult and adolescent participants who are at higher risk of developing influenza complications, and to evaluate the safety and tolerability of CD388, as compared to placebo.

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

DelRicht Research | Derby City Direct Primary Care - Louisville, KY

Site insights

Work at this site?

Active trials

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza (ANCHOR)

Trial sponsors